Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Capital Expenditures (2018 - 2026)

10x Genomics' Capital Expenditures history spans 8 years, with the latest figure at $80000.0 for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 100.96% to $80000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $215000.0, a 84.09% decrease, with the full-year FY2025 number at $215000.0, down 84.09% from a year prior.
  • Capital Expenditures hit $80000.0 in Q4 2025 for 10x Genomics, up from -$3.3 million in the prior quarter.
  • Over the last five years, Capital Expenditures for TXG hit a ceiling of $102.4 million in Q4 2022 and a floor of -$41.8 million in Q4 2023.
  • Historically, Capital Expenditures has averaged $11.9 million across 5 years, with a median of $3.2 million in 2023.
  • The widest YoY moves for Capital Expenditures: up 1282.6% in 2021, down 8681.23% in 2021.
  • Tracing TXG's Capital Expenditures over 5 years: stood at $27.6 million in 2021, then surged by 270.67% to $102.4 million in 2022, then plummeted by 140.86% to -$41.8 million in 2023, then surged by 80.09% to -$8.3 million in 2024, then skyrocketed by 100.96% to $80000.0 in 2025.
  • Business Quant data shows Capital Expenditures for TXG at $80000.0 in Q4 2025, -$3.3 million in Q3 2025, and $1.6 million in Q2 2025.